sLZIP Corepressor Complex Regulates Adipocyte Differentiation

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods for regulating the differentiation of mesenchymal stem cells into adipocytes and osteoblasts are inadequate, leading to disorders such as osteoarthritis and osteoporosis due to imbalanced adipogenesis and osteogenesis, and there is a need for effective therapeutic agents for diabetes and obesity.

Innovation Solution

Human small leucine-zipper protein (sLZIP) is used to inhibit the differentiation of mesenchymal stem cells into adipocytes by binding to PPARγ2, forming a complex with HDAC3 and acting as a corepressor to negatively regulate transcriptional activity, thereby balancing adipocyte and osteoblast differentiation.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Stability of the object's composition

If current methods are used to regulate differentiation of mesenchymal stem cells, then differentiation occurs, but the balance between adipogenesis and osteogenesis is disrupted leading to disorders

Engineering Contradiction:

Improvebalance between adipogenesis and osteogenesisVSAvoiddifferentiation regulation

Core Design Contradiction:

Stability of the object's compositionVSReliability

Solution Approach 1:

The patent introduces sLZIP as an intermediary molecule that mediates the interaction between PPARγ2 and HDAC3. This intermediary forms a corepressor complex that specifically targets adipogenic differentiation while preserving osteogenic potential, thereby maintaining the balance between adipogenesis and osteogenesis without disrupting overall differentiation regulation.

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent changes the transcriptional activity parameter of PPARγ2 by introducing sLZIP as a corepressor. This parameter change specifically downregulates adipogenic gene expression while maintaining osteogenic gene expression, thus adjusting the differentiation balance to prevent disorders like osteoarthritis and osteoporosis.

Inventive Principle:

Principle #35Parameter changes

2Productivity

If PPARγ2 transcriptional activity is increased to promote adipocyte differentiation, then adipogenesis is enhanced, but osteogenesis is suppressed leading to bone disorders

Engineering Contradiction:

Improveadipocyte differentiation efficiencyVSAvoidosteogenesis suppression

Core Design Contradiction:

ProductivityVSObject-affected harmful factors

Solution Approach 1:

The patent applies local quality by making the repression of PPARγ2 transcriptional activity specific to the adipogenic lineage. The sLZIP-HDAC3 corepressor complex selectively targets adipogenic differentiation pathways while leaving osteogenic pathways unaffected, thus reducing adipocyte overproduction without suppressing osteogenesis.

Inventive Principle:

Principle #3Local quality

Solution Approach 2:

Instead of directly inhibiting PPARγ2 to prevent adipogenesis, the patent uses sLZIP to recruit HDAC3 which then deacetylates histones at adipogenic gene promoters, indirectly repressing transcription. This inverted mechanism achieves adipogenesis control while preserving osteogenic potential.

Inventive Principle:

Principle #13The other way round (Inversion)

3Reliability

If transcriptional activity of PPARγ2 is not regulated, then adipocyte differentiation proceeds unchecked, but therapeutic agents for diabetes and obesity are lacking

Engineering Contradiction:

Improvedifferentiation controlVSAvoidtherapeutic application potential

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent employs sLZIP, an endogenous protein, to self-regulate PPARγ2 transcriptional activity through recruitment of HDAC3. This self-service mechanism provides intrinsic differentiation control that can be harnessed therapeutically for diabetes and obesity without requiring external synthetic agents.

Inventive Principle:

Principle #25Self-service

Solution Approach 2:

The sLZIP-HDAC3 corepressor complex serves multiple functions: it regulates adipocyte differentiation, maintains osteogenic potential, and provides a therapeutic target for both diabetes and obesity. This multi-functionality increases the adaptability and versatility of the differentiation control mechanism for various metabolic disorders.

Inventive Principle:

Principle #6Universality (Multi-functionality)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

sLZIP effectively inhibits adipocyte differentiation and regulates the balance of adipogenesis and osteogenesis, providing a therapeutic approach for diabetes and obesity by modulating the expression of genes involved in these processes.

Implementation Method 1

sLZIP binds to PPARγ2, forming a complex with HDAC3

Methodology Applied

Scientific EffectProtein-protein binding:

Data Source

PatentUS10058586B2Use of human small leucine zipper protein in adipocyte differentiation procedure

Publication Date: 2018.08.28 KOREA UNIV RES & BUSINESS FOUND

AI summary

The present invention relates to a use of a human small leucine zipper protein in the adipocyte differentiation procedure. More specifically, sLZIP binds with PPARγ2 to induce the formation of a complex of HDAC3 and PPARγ2, thereby functioning as a corepressor to negatively inhibit the transcriptional activity of PPARγ2 and suppress the differentiation to adipocytes, and thus can be used as a marker for treating diabetes and obesity and developing new medicines therefor.